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Abstract
Side effects are frequent in pharmacological pain management, potentially preceding anal-
gesia and limiting drug tolerability. Discussing side effects is part of informed consent, yet
can favor nocebo effects. This study aimed to test whether a positive suggestion regarding
side effects, which could act as reminders of the medication having been absorbed, might
favor analgesia in a clinical interaction model. Sixty-six healthy males participated in a study
“to validate pupillometry as an objective measure of analgesia”. Participants were unknow-
ingly randomized double-blind to positive vs control information about side effects embed-
ded in a video regarding the study drugs. Sequences of moderately painful heat stimuli
applied before and after treatment with diclofenac and atropine served to evaluate analge-
sia. Atropine was deceptively presented as a co-analgesic, but used to induce side effects.
Adverse events (AE) were collected with the General Assessment of Side Effects (GASE)
questionnaire prior to the second induced pain sequence. Debriefing fully informed partici-
pants regarding the purpose of the study and showed them the two videos.The combination
of medication led to significant analgesia, without a between-group difference. Positive infor-
mation about side effects increased the attribution of AE to the treatment compared to the
control information. The total GASE score was correlated with analgesia, i.e., the more AEs
reported, the stronger the analgesia. Interestingly, there was a significant between-groups
difference on this correlation: the GASE score and analgesia correlated only in the positive
information group. This provides evidence for a selective link between AEs and pain relief in
the group who received the suggestion that AEs could be taken as a sign “that help was on
the way”. During debriefing, 65% of participants said they would prefer to receive the posi-
tive message in a clinical context. Although the present results cannot be translated immedi-
ately to clinical pain conditions, they do indicate the importance of testing this type of
modulation in a clinical context.
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Introduction
Commonly used medications in pain management frequently have side effects, i.e. drug effects
that are secondary to the one intended. Side effects often limit drug tolerability or prevent
proper introduction especially in the context of chronic pain [1] [2]. In a study of pregabalin
for chronic neuropathic pain, 66% of patients (N = 224/338) experienced at least one side
effect, and 18% discontinued treatment due to this [3]. Crucially, communication about side
effects is delicate: providers have a legal and moral obligation to inform patients fully about
their treatment, but they should avoid inducing unnecessary worry or nocebo effects [4, 5].
This necessary discussion could perhaps be used to maximize the benefits of pharmacological
treatment or the tolerability of possible side effects ([6]).
Placebo effects are the enhancement of an actual or sham medication’s pharmacological
effects through positive expectancy and non-specific factors [7]. Placebo analgesia has been
shown to be modulated, for example, by prior treatment experience [8], anxiety [9], somatic
focus [10], as well as by information regarding the medication, such as drug value and brand
[11–13]. Furthermore, awareness that the therapy is being given impacts clinical effects, as
illustrated by open/hidden paradigms where analgesic doses are much less effective if the sub-
ject is not conscious of their delivery [14–16]. Evolutionary psychology theories have proposed
that self-healing processes could be favored by a third-party permission to recover, such as a
ritual or a healer [17]. Here we wondered whether patients could interpret side effects (i.e.
noticeable bodily sensations associated to the drug intake) as a third-party signal reminding
them that the medication is active in the body, hence conveying a message that “help is on the
way”.
There is some evidence to support this hypothesis. A double-blind randomized controlled
trial (RCT) of single doses of different agents for post herpetic neuralgia reported a correlation
between the number of side effects and pain relief [18]. In a more recent meta-analysis of
RCTs for irritable bowel syndrome, the difference in pain between drug and placebo groups
correlated with the difference in side effects [19]. The authors hypothesized that “patients feel-
ing the effects of the drug may associate this sensation with that of efficacy” [19]. This hypothe-
sis has been tested in an experimental double-blind RCT of a nonsteroidal anti-inflammatory
drug (NSAID) with and without a side-effect induced by atropine, deceptively presented as a
co-analgesic [20]. This study was the first experimental demonstration that the perception of
side effects in an analgesic RCT affects beliefs about treatment assignment, which in turn
increases the response to the medication.
The impact of side effects on therapeutic efficacy may be linked to the instruction that one
might receive a placebo. It is unknown if these findings could translate to a therapeutic setting,
where the patient is certain to receive active medication. To answer this question, we com-
pared the analgesia provided by an NSAID following a standard information about side effects
and an information containing a suggestion that side effects could be considered as a signal of
biological assimilation of the compound (i.e. a message of “help is on the way!”). The informa-
tion was provided in an experimental model of the clinical introduction of an analgesic com-
pound, with side-effect induction through atropine.
Method
1. Ethics statement
The protocol was approved by the local Ethic Committee: Swiss Cantonal Commission for
clinical research ethics, Canton Vaud, Switzerland (study registration number: CER_VD 215/
15) and was in accordance with principles of the Declaration of Helsinki, the Essentials of
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Good Epidemiological Practice issued by Public Health, and the Swiss Law as applicable. All
participants gave written informed consent.
2. Participants
Participants were recruited via advertisements posted on the University of Lausanne’s website
and campus advertisement boards. Men between 18 and 40 years old were phone-screened to
be healthy and fluent French speakers. Exclusion criteria were chronic intake of medication,
chronic pain, a psychiatric condition, or any condition (e.g. gastritis, high blood pressure, and
allergy) with increased risk for NSAIDs or atropine intake. We calculated a-priori that 26 partic-
ipants experiencing adverse event (AE) per condition would be sufficient to detect an effect size
comparable to that obtained in a previous study [d = 0.7], with 80% power [20]. Based on this
prior study reporting a 20% AE induction failure of atropine, a target of 33 participants in each
group was set. Seventeen screened volunteers were not eligible. The recruited sample consisted
of 66 healthy males aged 18–38 years (M= 24.3, SD = 4.1). The study was limited to males con-
sidering prior conflicting literature regarding differential gender-based responses to NSAIDs
and placebo modulations [21] [22]. Participants received CHF 50 to compensate for their time.
3. General procedure
The study was presented as aiming to “evaluate the subjective relief brought by a drug combi-
nation, and the correlation with an objective measure of pain, called pupillometry”. The pupill-
ometer (Neurolight Algiscan, IDMed, France) is a device validated for assessing reactivity to
noxious stimuli during anesthesia [23–25]. There is preliminary evidence that pupillometry
can be used as an objective measure of intense nociceptive stimulation in conscious people
[26, 27]. Little is known about lower intensity stimulation in an experimental context. Hence,
pupillometry was used as a cover story and as an exploratory measure. This partial study dis-
closure, omitting the randomization to two different conditions of information about drug
side effects, was maintained until the end of the study procedures when debriefing occurred.
Testing took place at the Pain Center at the CHUV, Lausanne, Switzerland, between May and
October 2016. Participants were invited for a single session lasting about 2h30 and were asked
not to eat any solids in the hour before coming to the Center in order to avoid interference
with medication absorption.
Unbeknown to them, participants were randomized 1:1 to positive vs. control information
about the experience of side effects provided through pre-recorded video messages (see details
of the information modulation below). Investigators involved in recruitment and testing (A.F.,
L.N., C.B.) were blind to the information condition. A collaborator (M.S.) prepared a coded,
randomized sequence of video assignments. The videos were shown on a laptop with a noise
canceling headset (see Fig 1).
First, vital signs were assessed and eligibility criteria were confirmed. Then the procedure
was explained to ascertain understanding; the first 3 min-long video was shown, and informed
consent was taken. In the video, the risks and benefits of the medications were disclosed. How-
ever, atropine was presented deceptively as an analgesic, whereas it was actually used to induce
AEs, mostly dry mouth [20]. Participants underwent heat pain calibration and a first test run
of experimental heat pain, used as a baseline. After watching a 1-minute long video-reminder,
all the participants received atropine 1.2mg (Streuli Pharma, Uznach, CH) and diclofenac
100mg (Novartis Pharma Schweiz AG) taken orally (Fig 1). Participants then went to a waiting
room where they filled questionnaires for 15 minutes (hope for relief, beliefs about medication
potency, anxiety, optimism, catastrophizing, anxiety sensitivity), followed by a 45 min wait for
the medication to fully become active. Salivary flow significantly decreases 50 min after
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administration of atropine [28], peak anti-inflammatory activity occurs 60 min after adminis-
tration of diclofenac [29]. After these 60 min, back in the testing room, participants reported
AEs on a standardized questionnaire [30] as well as a measure of expectation. Then they pro-
ceeded with the post-treatment experimental heat pain testing. Finally, participants were fully
debriefed regarding the additional purpose of the study and the effects of atropine.
4. Information modulation
Two sets of video-recorded messages (the main “consent” information video and the shorter
pre-drug intake “reminder”, see Fig 1) provided information about the study medications in
French by a 41-year-old male physician. The first 3-min video contained information about
the combination of diclofenac and atropine: mechanism of action (deceptive regarding the
atropine, presented as a co-analgesic), administration, and side effects. The second 1-min
video described the medication administration, pharmacokinetics, and a reminder about the
side effects. There were two versions of each of these videos, one containing a positive message
about side effects and a control version without this positive message.
The positive and control video sets were identical except for one sentence in the segment
about side effects. Both started with: “Side effects of this medication combination in healthy
volunteers are frequent, usually mild and without consequences. The most frequently reported
one is dryness of the mouth. In addition, some people experience visual accommodation
issues, feeling hot, having a hot, red or dry skin, jitteriness, dizziness or slight concentration
disruption. Decreases or increases in heart rate can be observed. All these will resolve within
2–4 hours of taking the medication.” Following this, in the “positive” information condition,
Fig 1. General procedure. Participants were randomized double-blindly to one of the two different information
conditions, watching a “consent” information video prior to signing consent. In this video, a physician described the
medication’s effects and side effects. The only difference between the two messages concerned side effects and is
summarized in the verbatim. After a calibration to determine the temperature eliciting moderate pain, heat pain
session 1 took place, with pain intensity Visual Analogue Scales (VAS), and pupillary dilation reflex (PDR) measures.
Then, the “reminder” video regarding side effects was watched before taking the study medication. At the beginning
and end of the 1-hour long break (while the medication was becoming active), participants filled Questionnaires (Q). A
second heat pain testing ensued, and the study concluded with a debriefing. STAI = state-trait anxiety inventory,
ASI = anxiety sensitivity Index, CAT = catastrophizing, LOT = life orientation test, D&B = desire and beliefs about
medication, GASE = General Assessment of Side Effects, Exp = expectation.
https://doi.org/10.1371/journal.pone.0209851.g001
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participants were told: “If you do experience a side effect, you might take this as a reminder that
the analgesic medication is active in your body, and that it will help you to perceive less pain.
Perhaps you can consider this as a signal that the drug is working”. In the “control” condition
the matching segment was: “If you do experience a side effect, do not hesitate to inform our
onsite staff, we will do our best to ensure your comfort". The information ended in both condi-
tions with thanks for participating and an invitation to ask questions to the onsite study team.
5. Measures
5.1 Pain stimulation. Initial heat pain stimulus calibration allowed to identify the individ-
ual temperature needed to elicit moderate (Mod) pain ratings, i.e. rated about 5 on a 10 cm
Visual Analogue Scale (VAS) (Mean VAS rating = 5.1, SD = 1.0). This was performed by
applying different test temperatures (ladder method) to a 10-second thermal stimulus deliv-
ered on the left forearm (TSA-II, Medoc, Ramat Yishai, Israel) (19, 30) in order to observe a
reproducible pain rating. This calibration also ascertained that Mod +1˚C was intensely pain-
ful but tolerable (Mean VAS rating = 6.5, SD = 1.2), and Mod -0.5˚C as well as -1˚C were per-
ceived on average, as low pain (Mean VAS rating = 2.7, SD = 1.6).The pre- and post-treatment
testing consisted in the same sequence of ten stimuli: Mod / Mod / Mod-0.5˚C / Mod / Mod
+1˚C / Mod / Mod / Mod-1˚C / Mod / Mod.
Subjects rated the pain intensity of each stimulus on a 10 cm-VAS (with anchors of “no
pain” and “most intense pain imaginable”) [31] during 10-30s variable interstimulus intervals.
The mean rating of pain intensity from the 7 repetitions of moderate stimuli (Mod) was the
outcome of interest, with the other 3 interspersed stimuli intended as distracters [20, 32]. Anal-
gesia was calculated as the difference in the mean of the 7 VAS (Mod) between pre- and post-
treatment sequences.
5.2. Adverse events reporting. One hour after medication intake, the participants filled
the Generic Assessment of Side Effects (GASE) [30]. This standardized questionnaire requires
the participant to rate the severity of 36 adverse events (AEs) on a scale (0 = not present,
1 = mild, 2 = moderate, 3 = severe) and to categorize each present AE as related to the study
medication (attributed AE) or not. This allows computing four indices: 1) A count of reported
AE: with a score�1 (Number of AE), 2) number of AE attributed to the medication (attrib-
uted AE), 3) total GASE score (sum of intensity ratings on all items), and 4) Medication-attrib-
uted GASE score (Rief, Glombiewski & Barsky 2009: Generic Assessment of Side Effects.
www.GASE-scale.com). A ‘mean intensity of AEs’ was computed by dividing the GASE by the
number of AEs, considering only participants with�1 AE, both for total and attributed AEs.
As AEs were not expected to be severe, but could be unpleasant, an additional measure of AE
unpleasantness was collected on a VAS, with anchors from 0 (not at all) to 10 (intolerable).
5.3. Pupillometry. The pupillary reflex was measured by an infrared portable dynamic
pupillometer (NeuroLight). Measurements were performed with the device’s rubber cup cov-
ering the measured eye (left eye) and the participant’s right hand covering the right eye. The
device assesses the baseline pupillary size as well as the pupillary dilatation reflex (PDR), i.e.
the variation of the pupillary diameter over the course of the painful stimulation, expressed in
percent. The recording was initiated as the thermal stimulus started, and stopped after 12 sec-
onds. This measure was repeated 5 times using a second, shorter sequence of stimuli (Mod /
Mod / Mod-0.5˚C / Mod / Mod+1˚C). This sequence of measures occurred right after the pre-
and post-treatment sequence of 10 stimuli with the VAS ratings. Only pre-treatment PDR
measures were analyzed as atropine can affect the post-treatment pupillary diameter and PDR.
5.4. Desire, beliefs, expectations, and psychological characteristics. An effect of the
information modulation on desire for relief beliefs, and expectations was measured [33, 34].
A test of positive suggestions about side effects as a way of enhancing the analgesic response to NSAIDs
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Participants rated: 1) just after taking the medication “How much would you like to be relieved
by the combination of medication?” as well as: “How efficient do you believe the medication
combination to be against heat pain?” on 10-cm VAS anchored from “not at all” to “extremely”
and 2) after having reported AEs, “How much relief do you expect from the combination of
medication?” on a VAS ranging from “no relief” to “complete relief”.
In order to control for possible moderators, anxiety (measured using State and Trait anxiety
inventory, STAI (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983) and Anxiety Sensitivity
Index, ASI [35]), optimism (LOT [36]), and in vivo catastrophizing (6-item scale derived from
the Pain Catastrophizing Scale [37]) were evaluated. In addition, prior to the first calibration,
participants gave a baseline VAS evaluation of their anxiety, focus, and tiredness. All data were
collected and managed using REDCap electronic data capture tools hosted at the University of
Lausanne [38].
5.5. Debriefing preference regarding information and estimation of the effects of infor-
mation. During the final debriefing, participants were shown the two different “reminder”
video segments about side effects. Afterward, they were asked which type of information (posi-
tive or control) they would prefer to receive from their doctor at the beginning of a new treat-
ment. They were asked not to disclose which one they saw during the test sequence.
Finally, participants’ estimation regarding a potential effect of the positive information on
the efficacy of the treatment “Do you think that this explanation could enhance the effects of
the treatment?” was also rated on a VAS ranging from 0 (no effect at all) to 10 (very much
effect).
6. Statistical analysis
The primary outcome was the reduction in moderate pain intensity following treatment (i.e.
analgesia, post- minus pre-treatment moderate pain ratings). We used a 2x2 (group by treat-
ment) mixed model ANOVA to test for differences in pain scores with group as a between sub-
ject factor and pre- versus post-treatment as a repeated measure. The secondary outcomes
were AEs reports (unpaired t-tests for group comparison) and the relationship between anal-
gesia and AEs (Pearson’s correlations). The Group factor was examined as a potential modera-
tor of the correlation between AEs and analgesia, by regressing analgesia on the interaction
term (group x AEs), controlling for group and number of AEs.
In order to assess possible baseline group differences despite randomization, participant’s
characteristics were compared with unpaired t tests.
As a further manipulation check, chi-square tests of homogeneity were calculated compar-
ing the preference of information between groups.
Exploratory analyses were conducted without correction for multiple comparisons except
for the pupillometry data: a) The relationships between analgesia and measures of desire,
expectations, and beliefs (Pearson’s correlations). b) The relationship between psychological
variables (anxiety, optimism, catastrophizing) and the number of AEs was explored through
Pearson’s correlations. c) VAS and PDR between low, moderate, and intense stimuli were
compared through ANOVAs followed by Bonferroni corrected post-hoc multiple comparisons
and correlated using Pearson’s correlations.
SPSS 23.0 (IBM Statistics) was used to conduct these analyses.
Results
1. Participant characteristics
The participants (N = 33 healthy males in each group) randomized to the different information
conditions (positive or control) did not differ significantly in age, temperature eliciting
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moderate pain, pre-treatment moderate pain rating, optimism, anxiety, catastrophizing, beliefs
about the medication potency, desire for, or expectations of relief (See Table 1).
2. Analgesia
Treatment induced analgesia in both positive (M = -1.05, SD = 1.22) and control (M = -1.03,
SD = 1.17) information groups (i.e. a significant effect of the treatment) [F(1,32) = 48.76, p <
.001], without a significant group effect [F(1,32) = .34, p = .57] or group by treatment interac-
tion [F(1,32) = .01, p = .93] (Fig 2). The same analysis led in the population of participants
who did experience adverse events (AEs) presented similar results (significant treatment effect:
[F(1,27) = 53.92, p< .001]; no group effect: [F(1,27) = .00, p = .99]; nor interaction: [F(1,27) =
.00, p = .99]).
Table 1. Participants’ characteristics.
Control group (n = 33) M (SD) Positive group (n = 33) M (SD) Group difference
p value
Correlation with analgesia
r; p value
Age, years 24.2 (4.0) 24.5 (4.3) .76 -.12; p = .33
Anxiety, NRS/10 1.7 (2.1) 2.4 (2.4) .25 .06; p = .64
Focused, NRS/10 7.7 (1.7) 7.6 (1. 8) .78 -.00; p = .98
Tired, NRS/10 3.8 (2.1) 3.2 (2.1) .27 -.02; p = .87
Calibration for moderate pain, ˚C 46.4 (1.7) 46.0 (1.6) .33 -.04; p = .76
Pre-treatment pain ratings, VAS/10 4,8 (1.2) 5.0 (0.8) .47 -.14; p = .25
State-Trait Anxiety Inventory-State (STAI-S) 28.3 (8.8) 30.9 (8.6) .22 .06; p = .61
State-Trait Anxiety Inventory-Trait (STAI-T) 34.2 (9.0) 37.0 (9.2) .20 -.03; p = .82
Anxiety Sensitivity Index (ASI) 15.3 (7.5) 18.2 (8.0) .14 .12; p = .32
Pain catastrophizing scale (CAT) 1.6 (1.7) 2.3 (2.3) .19 .09; p = .47
Life Orientation Test (LOT) 16.6 (4.8) 15.1 (4.2) .17 .06; p = .64
Desire for relief (VAS 0–10) 6.4 (2.2) 6.7 (2.3) .61 .18; p = .14
Belief of efficacy (VAS 0–10) 6.0 (1.6) 6.0 (1.9) .95 .05; p = .69
Expectations of relief (VAS 0–10) 5.9 (1.9) 6.5 (4.1) .42 .03; p = .81
M = mean, NRS = numerical rating scale; VAS = visual analogue scale.
https://doi.org/10.1371/journal.pone.0209851.t001
Fig 2. Pain intensity scores before and after treatment, according to information group. The analgesic and atropine
combined treatment had a significant effect on pain intensity ratings of moderate heat pain stimuli (mean of seven
stimuli) without significant difference between information groups regarding adverse events (either positive or control
information). VAS = Visual Analogue Scale; Error bars are SD; ��� p< .0001.
https://doi.org/10.1371/journal.pone.0209851.g002
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3. Adverse events
The majority of participants (59/66, i.e. 89%) reported at least one adverse event (AE) 1h
after medication intake, the most frequent ones were dry mouth (49/66), fatigue (16/66),
headache (10/66), and vertigo (6/66). Between-group differences in adverse events are pre-
sented in Fig 3. The total GASE score was not significantly different between the two groups
(control: M = 2.97, SD = 2.91 vs positive: M = 2.76, SD = 2.16, t(64) = .34 p = .74). The
between-group difference in medication-attributed GASE scores failed to reach statistical
significance (control: M = 1.21, SD = 1.24 vs positive M = 1.94, SD = 1.92), t(64) = -1.83
p = .07.
Given that the GASE is a composite score combining the number of side effects and their
intensity, these factors were studied separately. There was no significant difference in mean
number of total AEs reported by the positive (M = 2.49, SD = 1.77) vs the control group
(M = 2.30, SD = 2.13); t(64) = .38 p = .71 but those in the positive information group attributed
significantly more AEs to the treatment (M = 1.70 SD = 1.44) than those in the control infor-
mation group (M = .91 SD = .84); t(64) = -2.70 p< .01 (Fig 3). The mean intensity of the per-
ceived AEs was significantly higher in control group (control: M = 1.23 SD = .32 vs positive
M = 1.08 SD = .18), t(42.4) = 2.2 p = .03, but intensity differences in AEs attributed to treat-
ment (control: M = 1.32 SD = .53 vs. positive M = 1.08 SD = .20) was not significant, t(26.6) =
2 p = .06. Hence, the positive information group reported more AEs, with lesser intensity. The
mean and maximum unpleasantness of these attributed AEs did not differ significantly
between groups (Mean unpleasantness: MPostive = 1.47, SD = 1.29; MControl = 1.63, SD = 1.80,
t(63) = .42 p = 0.06; Maximum unpleasantness: MPostive = 1.75, SD = 1.95 vs MControl = 1.77
SD = 1.75, t(63) = -.05 p = .49).
Fig 3. Group comparisons of the Generic Assessment of Side Effects (GASE) score, and its sub-components
(number of adverse events (AEs) and intensity) for total and attributed AEs. For total AEs, the GASE score and
number of AEs was not significantly different between information groups (A,B), however, the intensity of AEs was
stronger in the control group (C). For the attributed AEs, the GASE score difference was not significant (D), the
number of AEs attributed to the treatment was higher in the positive group (E). There was no significant between
group difference in the mean intensity of attributed AEs (F). Note that the intensity of AEs (E) (and attributed AEs (F))
is only calculated for those who reported AEs (and attributed AEs to the medication (F)), hence the decreased N of
participants. Error bars represent mean +/- SD.
https://doi.org/10.1371/journal.pone.0209851.g003
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4. Interaction between analgesia and adverse events
Both total GASE score and medication attributed GASE score were correlated with analgesia
(Fig 4); i.e., the more AEs are perceived (whether attributed to treatment or not) the stronger
the analgesia (total GASE: r = -.41 p = .01; medication-attributed GASE: r = -.34 p< .01).
Group differences in correlations were significant for total GASE score (interaction term p =
.02), with a correlation between GASE score and analgesia significant in the positive group
(r = -.63 p< .001) but not in the control one (r = -.25, p = .16). Differences in correlations
were not significant for medication attributed GASE score (interaction term = .57).
5. Debriefing questions: Preferred information and estimation of the effect
of information
During the debriefing, after watching consecutively the two different abbreviated video seg-
ments about side effects, 65% (43/66) of the participants said they would prefer to receive the
positive message in a clinical context. Subjects in the positive group were more likely to prefer
the positive information than those in the control information group. In the positive group,
85% preferred the positive information whereas in control group 45% preferred the positive
information, X2(1, N = 66) = 11.28, p = .001.
There was no significant difference between positive and control information groups in
participant’s debriefing estimation of potential benefits of the positive information on the effi-
cacy of the treatment, all finding it rather effective (no effect at all = 0, very much effect = 10)
[Mpositive = 6.1 SD = 2.24; Mneutral = 5.46 SD = 2.51; t(64) = -1.1, p = .28]. However, there was a
correlation between medication-attributed GASE score and participant’s belief of efficiency
(r = .31, p = .01) i.e. the more AEs people attribute to the medication, the more effective they
think the positive information is at improving treatment outcomes.
6. Expectations and measure of desire and beliefs
Measures of expectations, desire and belief did not correlate with analgesia (Table 1), nor with
the total GASE score (expectation: r = -.01, p = .92; desire: r = .17, p = .18; beliefs: r = .12, p =
.33). These different expectation-related measures collected at different time points correlated
Fig 4. Correlations between analgesia and (A) the total GASE score and (B) the medication-attributed GASE score. Significant
negative correlations were found between analgesia (VAS post–VAS pre-treatment) and total GASE score, and medication-
attributed GASE score, i.e. more analgesia was perceived when more side effects were reported. Yet, this correlation was significant
only in the positive information groups (A1, B1). The difference in correlations between the positive and control information group
was significant for the correlation between analgesia and the total GASE score, but not for the medication attributed GASE score
(comparison A1 vs. A2 and B1 vs. B2).
https://doi.org/10.1371/journal.pone.0209851.g004
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with each other (desire X beliefs: r = .49, p < .001; desire X expectation: r = .35, p< .01; beliefs
X expectation r = .38, p = .01).
7. Psychological variable scores
Correlations indicated that the less optimistic one is (LOT score) the more AEs one perceives
(total GASE score; r = -.27; p = .029) and one attributes to medication (medication-attributed
GASE score; r = -25; p = .048). Anxiety sensitivity (ASI score) was also correlated with the total
GASE score (r = .26; p = .035) and the medication-attributed GASE score (r = .30; p = .016)
indicating the more anxious one is, the more side effects one perceives and attributes to the
medication. There was no significant correlation between the other psychological scores and
AEs reporting.
8. Correlation between pre-treatment pupillometry and subjective pain
scores
There were significant effects of intensity on VAS [F (2, 525) = 180.3, p< .0001] and on PDR
[F (2, 327) = 3.75, p = .03]. VAS scores were significantly different for low, moderate, and
intense conditions (adjusted p<0.001). For the PDR measure, only moderate and intense con-
ditions were significantly different (adjusted p = .02) (Fig 5). There was unsurprisingly no sig-
nificant correlation between VAS and PDR (low stimuli: r = -.01, p = .94; moderate stimuli: r =
-.01, p = .91; intense stimuli:r = -.23,p = .07).
Discussion
This study aimed at framing side effects as a signal of assimilation of the medication in order
to enhance NSAID analgesia. Although the combination of medication led to significant
analgesia, the between-group difference was not significant. On the other hand, positive infor-
mation about side effects did increase the number of them attributed to the medication. Fur-
thermore, a correlation was observed between analgesia and the perceived side effects (GASE
score) in the positive information group but not in the control one. This suggests that positive
information did specifically tie side effects to analgesia, as hypothesized. After debriefing, and
watching both information segments about side effects, a majority preferred the positive one.
Interestingly, the positive framing of side effects led to more attribution of adverse events to
medication. Participants reported more numerous AEs compared to the control information
suggesting that the positive information about side effects has led to hypervigilance. The
Fig 5. Pain intensity ratings (panel A) and pupillometry response (panel B) depending on the calibrated stimuli
that were applied. The pain VAS ratings differed significantly between the applied stimuli that were calibrated as low,
moderate and intense (A). Only moderate and intense stimuli conditions elicited significantly different pupillometry
responses (B). VAS = visual analogue scale; PDR = pupillary dilatation reflex; ���� p< .0001 � p< .05.
https://doi.org/10.1371/journal.pone.0209851.g005
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quantity and contents of information about side effects can play a critical role in side effect
reporting and attribution [4, 39, 40]. In our case, both groups received an equal amount of
information. However, we devised a sentence-long positive interpretation of their occurrence,
suggesting they act as a reminder that the medication has been ingested, intended to favor a
placebo-like effect. This suggestion was rooted in research showing that medical rituals and
other signs of active treatment can induce favorable expectations or a positive bias [15, 17, 41].
Also, side effects have been shown to lead to unblinding and to increased analgesia in a prior
experimental model of clinical trial [20]. To our knowledge, this is the first study that used ver-
bal suggestions to tie side effects and analgesia in a clinical interaction model. Side effects rely
on bodily sensations experienced after the intake of a drug and that are subsequently attributed
to it (or not). Side effect attribution is thus an important aspect in their report [42, 43] and is a
frequent reason for withdrawing from a clinical trial or discontinuing a medication. The tested
information may have led to detection at lower threshold, hypervigilance, or over-attribution
of side effects since they were described as a favorable event in our study. Also, negative affect
and anxiety have been linked to increased side effect perception and attribution to medication
[5]. In fact, our exploratory analysis revealed a correlation between anxiety sensitivity and side
effects reporting.
Our aim was to enhance analgesia in the positive information group compared to control
group, which we failed to corroborate. Yet, analgesia was higher for those experiencing more
side effects, as revealed by the correlation of analgesia with the GASE score in the positive but
not in the control information group.
Various reasons could explain why the increased analgesia was not found in the whole posi-
tive information group, as initially hypothesized. One could argue the message was too subtle:
only one sentence, embedded in a 3-min information video and in a 1 min reminder segment,
suggested a positive link between side effects and analgesia. Yet group-differences were found,
and perhaps emphasizing the suggestion more would have felt unnatural.
A second possibility is that atropine induced too few and too mild AEs in each participant.
In a previous study, atropine led to noticeable symptoms in about 80% of subjects; this was
taken into account in the power calculation (see “participants” in methods). Here, as expected,
thirteen participants did not experience any AEs, yet with an uneven repartition of this failure
to induce AEs: 10 (30%) in the control group, 3 (9%) in the positive group. About half of the
participants experienced only dry mouth (34/66), and a small minority (11%) experienced
more than two AEs. Given the correlation between number of AEs per participant and experi-
enced analgesia, perhaps this is an important (although unexpected) factor. Possibly, partici-
pants with few AEs doubted the positive information, undermining the suggestion. Perhaps
inducing stronger or more side effects would have shown group differences in analgesia. Yet
this might be practically difficult and ethically questionable. Nevertheless, in a clinical context,
side effects are much more relevant. Hence, an intervention focusing on patients at risk of side
effects, based on personality traits [5] and tying them to outcomes could possibly be useful.
During debriefing, participants in the positive information group preferred the information
suggesting that side effects act as reminders of the medication’s activity in the body, whereas
those in the control group did not. Furthermore, when asked to evaluate how much the posi-
tive information could enhance the effects of a medication in a hypothetical clinical scenario,
all participants gave on average a high rating, often spontaneously mentioning possible placebo
effects. Interestingly, in both groups, the more participants perceived side effect, the higher
they rated the possible benefits of such information on treatment outcomes. This could have to
do with a bias induced by experience (“preferring/justifying the outcome one has received”
[44]). Participants who preferred the positive information argued that the message was “reas-
suring”, “more optimistic”, and “helped to prepare themselves to side effects and to accept
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them”. Those who preferred the control information mostly argued against the positive mes-
sage, which “forces the interpretation”, “is a manipulation”, “induces side effects”, and “trivial-
izes side effects”. Some of them hypothesized that “if a patient does not experience side effects,
he could think the medication is not active”. In fact, the three participants in the positive infor-
mation group, who reported no AEs presented almost no analgesia (mean: -0.07 point differ-
ence on the VAS score vs. full sample mean: -1.05).
Finally, it may be that an enhancement of therapeutic outcomes by side effects could be lim-
ited to RCTs: it has been shown in a prior study that their perception can be used by partici-
pants to detect whether they have been randomized to drug or placebo, and thereby benefit
from increased analgesia [20]. Yet, we do find a correlation between side effect reports and
analgesia that is specific to the group having been exposed to the positive information. This
suggests an effect that might require greater power to be detected more widely. In addition, as
the sample size was calculated based on the primary outcome (analgesia), without considering
the uneven repartition of adverse events, some of the secondary outcomes, such as the correla-
tion analysis might be underpowered. Additional experiments should be performed on larger
samples to fully explore the interaction between information, side effects and analgesia, allow-
ing to include measures of psychological traits on the analyses.
Expectations, beliefs about medication, and desire for relief were measured as possible
mediators of positive information about side effects on analgesia since treatment effects can be
modulated by these factors [33, 45]. However, these elements did not differ between the two
groups of information, nor did they correlate with side effects or analgesia, although these
exploratory analyses might be underpowered. Hence, we did not manage to capture the medi-
ating factor impacted by the positive information regarding side effects. The relatively low cor-
relation between beliefs about medication potency and expectation of relief is interesting,
since they are similar constructs, both of which might be used as a measure of expectancy. This
might reflect a change of expectations between measures collected before medication intake
(belief and desire) and after noticing side effects (the expectation of relief). However, the differ-
ence in wording between the two measures makes it impossible to test directly.
Lastly, this study delivered suggestions through a video-taped message. Previous studies
have shown that multimedia communications are well understood and retained, suggesting
this is not a limitation to participants’ ability to integrate the provided information [46, 47]. In
the debriefing, none of the participants questioned the credibility of the video nor of the physi-
cian appearing in it. Nevertheless, pre-recorded communication meant the message was
detached from a relationship with a treating physician or a study experimenter which might
have implications on the power of the suggestion [48]. In fact, although the physician had the
necessary characteristics to build a good relationship, i.e. he appeared empathic, serious and
reassuring, [49, 50], he was not present in the room. Whether the practitioner can efficiently
incarnate the “heroic rescuer” who can “facilitate a placebo effect” (in the words of [51]) also
on a screen, is an open question to be answered by future studies comparing face to face to
video-recorded messages.
The video set-up insured proper blinding of the study staff interacting with the participants,
contrary to a number of therapeutic suggestion studies where the researcher delivering the
message appeared to be aware of the design and research question e.g. [33, 52, 53]. In such
prior studies, the unblinded study staff might have enriched the relationship with the partici-
pants in the positive condition or deprived those in the control condition. For example, in
addition to the scripted suggestion under investigation, empathic touch, and other nonverbal
communication could have been modulated [50].
Unsurprisingly, given prior reports of correlations only between very intense painful sti-
muli and pupillary reflex amplitude, there was no correlation between PDR and VAS ratings
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[26, 27]. A recent study using an experimental heat pain protocol with healthy volunteers also
demonstrated that the pupillary response was more related to the stimulus intensity than to
subjective pain perception [54]. As argued by another group, measures of sympathetic auto-
nomic responses might rather reflect nociceptive processes than subjectively perceived pain
[55].
In conclusion, thanks to this experimental model, we have answered preliminary and fun-
damental questions regarding a possible paradigm shift in the communication about side
effects. We determined that a positive framing of side effects was credible, even preferred by
the majority of participants to whom it is given, and effective in tying them to analgesia, pro-
vided there were enough perceived side effects. Although these results are promising, they
were obtained in healthy volunteers with transient and mild side effects tied to acute induced
pain. Given that these results suggest feasibility and validity of investigating positive communi-
cation regarding side effects in a clinical context, the next step could be to evaluate such a
framing in actual patients when introducing medication with a high prevalence of side effects.
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